Although current PARPi trials are primarily focusing on BRCA1 and BRCA2 mutations, cancers that do not have BRCA mutations may still be vulnerable to PARPi therapy, as other alterations such as ATR, PALB2, and the members of the FANC gene family15 can confer a BRCA-like status.15 Here, ATR is linked to cancer.